Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06585345 | Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia | recruiting | Phase 1 / Phase 2 | 200 | The General Hospital of Western Theater CommandOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06341556 | A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma | recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT06553352 | Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma | recruiting | Phase 2 | 39 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06569485 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients | recruiting | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT04838652 | Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma(Pembro-CORE) | recruiting | Phase 2 | 29 | University of CologneOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT02131753 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | recruiting | Phase 2 / Phase 3 | 210 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06221683 | Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML(GMCAII) | recruiting | Phase 2 | 500 | Children's Hospital of Soochow UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06316960 | Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation | recruiting | Phase 2 | 50 | Children's Hospital of Soochow UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566807 | Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 51 | Huai'an First People's HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06479356 | CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma | recruiting | Phase 2 | 12 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06554626 | Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL | recruiting | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06536959 | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS | recruiting | Phase 2 | 67 | Beijing 302 HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06537843 | Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia(VenCM) | recruiting | Phase 2 | 100 | Hospital Municipal São JoséOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06532084 | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen(SoraGVL) | recruiting | Phase 2 | 88 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06508099 | Vitamin A and D Supplementation in Allogeneic HCT(VitaStem) | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04837859 | Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma(INDIE) | recruiting | Phase 2 | 120 | University of CologneOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | recruiting | Phase 2 | 39 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06513234 | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | recruiting | Phase 2 | 45 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05159245 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE) | recruiting | Phase 2 | 250 | Helsinki University Central HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT05636787 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients(TreoMel) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06430736 | PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)(PRONTO) | recruiting | Phase 2 | 100 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05870475 | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV(PV) | recruiting | Phase 2 | 94 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06482684 | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma(CARMAN) | recruiting | Phase 2 | 150 | Christian Schmidt, MDOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06477549 | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06454968 | Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. | recruiting | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06462248 | Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies | recruiting | Phase 2 | 20 | Chi Kong LiOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06461182 | Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma(PentixaFor) | recruiting | Phase 2 | 15 | Koo Foundation Sun Yat-Sen Cancer CenterOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05248633 | Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma | recruiting | Phase 2 | 220 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT04905810 | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | recruiting | Phase 2 | 20 | Brian JonasOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence(CAPTiRALL) | recruiting | Phase 1 / Phase 2 | 26 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05580861 | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment(SALMA) | recruiting | Phase 1 / Phase 2 | 64 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05868395 | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04061512 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia(RAINBOW) | recruiting | Phase 2 / Phase 3 | 148 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06002659 | CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)(CARMA-01) | recruiting | Phase 1 / Phase 2 | 18 | Uppsala UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05869279 | Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 29 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation(EVI-3) | recruiting | Phase 2 | 196 | Kirsten GrønbækOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | recruiting | Phase 2 | 89 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 12 | Apr 15, 2024 | clinicaltrials |
| NCT05791409 | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL(AETHER) | recruiting | Phase 1 / Phase 2 | 112 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Apr 12, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06250959 | RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.(BEAT-ALL-2024) | recruiting | Phase 2 | 124 | Chen SuningOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05477264 | Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type | recruiting | Phase 2 | 38 | Won Seog KimOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06321289 | Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06232096 | A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | recruiting | Phase 1 / Phase 2 | 154 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06046313 | Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS | recruiting | Phase 2 | 120 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 5, 2024source: clinicaltrials